A role for the mu opioid receptor in the antidepressant effects of buprenorphine.
Buprenorphine (BPN), a mixed opioid drug with high affinity for mu (MOR) and kappa (KOR) opioid receptors, has been shown to produce behavioral responses in rodents that are similar to those of antidepressant and anxiolytic drugs. Although recent studies have identified KORs as a primary mediator of BPN's effects in rodent models of depressive-like behavior, the role of MORs in BPN's behavioral effects has not been as well explored. The current studies investigated the role of MORs in mediating conditioned approach behavior in the novelty-induced hypophagia (NIH) test, a behavioral measure previously shown to be sensitive to chronic treatment with antidepressant drugs. The effects of BPN were evaluated in the NIH test 24h post-administration in mice with genetic deletion of the MOR (Oprm1-/-) or KOR (Oprk1-/-), or after pharmacological blockade with the non-selective opioid receptor antagonist naltrexone and selective MOR antagonist cyprodime. We found that behavioral responses to BPN in the NIH test were blocked in Oprm1-/-mice, but not in Oprk1-/-mice. Both cyprodime and naltrexone significantly reduced approach latency at doses experimentally proven to antagonize the MOR. In contrast the selective MOR agonist morphine and the selective KOR antagonist nor-BNI were both ineffective. Moreover, antinociceptive studies revealed persistence of the MOR antagonist properties of BPN at 24h post-administration, the period of behavioral reactivity. These data support modulation of MOR activity as a key component of BPN's antidepressant-like effects in the NIH paradigm.
Departments of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, United States.
Shivon A
SA
Robinson
Pathobiology, University of Pennsylvania, Philadelphia, PA 19104, United States.
Rebecca L
RL
Erickson
Departments of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, United States.
Caroline A
CA
Browne
Departments of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, United States; Pharmacology, University of Pennsylvania, Philadelphia, PA 19104, United States. Electronic address: irwin.lucki@usuhs.edu.
Irwin
I
Lucki
D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects*; D002047:Buprenorphine / Q000494:pharmacology*; D005247:Feeding Behavior / Q000187:drug effects; D001068:Feeding and Eating Disorders / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009019:Morphinans / Q000494:pharmacology; D009271:Naltrexone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D010147:Pain Measurement / Q000187:drug effects; D011930:Reaction Time / Q000187:drug effects; D017473:Receptors, Opioid, kappa / Q000172:deficiency / Q000235:genetics; D017450:Receptors, Opioid, mu / Q000235:genetics / Q000378:metabolism*
D000928:Antidepressive Agents; D009019:Morphinans; D009292:Narcotic Antagonists; C404943:Oprm protein, mouse; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; C058450:cyprodime; D002047:Buprenorphine; D009271:Naltrexone
Antidepressant; Buprenorphine; Endogenous opioid system; Novelty-induced hypophagia